主动监测中重复MRI的前列腺病灶自然史与升级率
该回顾性研究纳入558例前列腺癌主动监测患者,评估系列多参数MRI进展标准与病理升级的关系。结果显示首次重复MRI约27%患者出现进展,但后续MRI进展率随时间下降;序列mpMRI的阴性预测值高(ISUP GG≥3升级为98%-99%),mpMRI稳定且PSAD<0.15 ng/mL/mL者可安全跳过活检。
要点
- 首次重复MRI约27%患者出现mpMRI进展,但后续进展率随时间下降。
- 序列mpMRI对ISUP GG≥3升级的阴性预测值为98%-99%。
- mpMRI稳定且PSAD<0.15 ng/mL/mL者可安全跳过监测活检。
核心结论
- 主动监测中约27%患者首次重复MRI出现mpMRI进展,但后续MRI进展率随时间下降。
- mpMRI稳定且PSAD<0.15 ng/mL/mL的患者可安全跳过监测活检;出现mpMRI进展者应行前列腺活检。
研究设计与样本
- 回顾性分析558例接受主动监测的前列腺癌患者。
- 采用5种mpMRI进展标准:PI-RADS评分升高、病灶大小增加、包膜外侵犯评分升高、整体mpMRI进展、满足进展标准数目(0 vs 1 vs 2-3)。
- 评估两种前列腺癌升级定义:ISUP GG≥2且pattern 4>10%和ISUP GG≥3。
- 使用估计年度百分比变化法展示mpMRI进展标准的时间趋势,并分析敏感性、特异性、PPV和NPV。
- 多变量逻辑回归模型检验前列腺癌升级率。
主要发现
- 所有mpMRI进展标准随时间呈较低发生率。
- 序列mpMRI扫描的NPV范围:ISUP GG≥2且pattern 4>10%升级为90.5%-93.5%,ISUP GG≥3升级为98%-99%,取决于所用mpMRI进展标准。
- 多变量逻辑回归模型中,所有5种mpMRI进展标准均达到独立预测因素地位。
关键数值与推荐
- PSAD阈值0.15 ng/mL/mL用于分层可跳过前列腺活检的患者。
- mpMRI进展标准包括PI-RADS评分升高、病灶大小增加、包膜外侵犯评分升高、整体mpMRI进展及满足标准数目(0 vs 1 vs 2-3)。
- 前列腺癌升级定义:ISUP GG≥2且pattern 4>10%,或ISUP GG≥3。
临床怎么用
- 主动监测患者首次重复MRI约27%出现进展,但后续进展率下降,应关注序列MRI动态变化。
- mpMRI稳定且PSAD<0.15 ng/mL/mL者可安全跳过监测活检。
- 出现mpMRI进展的患者应接受前列腺活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess upgrading rates in patients on active surveillance (AS) for prostate cancer (PCa) after serial multiparametric magnetic resonance imaging (mpMRI). METHODS: We conducted a retrospective analysis of 558 patients. Five different criteria for mpMRI progression were used: 1) a Prostate Imaging Reporting and Data System (PI-RADS) score increase; 2) a lesion size increase; 3) an extraprostatic extension score increase; 4) overall mpMRI progression; and 5) the number of criteria met for mpMRI progression (0 vs 1 vs 2-3). In addition, two definitions of PCa upgrading were evaluated: 1) International Society of Urological Pathology Grade Group (ISUP GG) ≥2 with >10% of pattern 4 and 2) ISUP GG ≥ 3. Estimated annual percent changes methodology was used to show the temporal trends of mpMRI progression criteria. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of mpMRI progression criteria were also analysed. Multivariable logistic regression models tested PCa upgrading rates. RESULTS: Lower rates over time for all mpMRI progression criteria were observed. The NPV of serial mpMRI scans ranged from 90.5% to 93.5% (ISUP GG≥2 with >10% of pattern 4 PCa upgrading) and from 98% to 99% (ISUP GG≥3 PCa upgrading), depending on the criteria used for mpMRI progression. A prostate-specific antigen density (PSAD) threshold of 0.15 ng/mL/mL was used to substratify those patients who would be able to skip a prostate biopsy. In multivariable logistic regression models assessing PCa upgrading rates, all five mpMRI progression criteria achieved independent predictor status. CONCLUSION: During AS, approximately 27% of patients experience mpMRI progression at first repeat MRI. However, the rates of mpMRI progression decrease over time at subsequent mpMRI scans. Patients with stable mpMRI findings and with PSAD < 0.15 ng/mL/mL could safely skip surveillance biopsies. Conversely, patients who experience mpMRI progression should undergo a prostate biopsy.
引用
- Luzzago S, Piccinelli ML, Mistretta FA, et al. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU Int. 2021. PMID: 34687137. doi:10.1111/bju.15623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。